AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Why now
Thesis: EU label expansion widens RINVOQ patient pool, supporting incremental revenue.
Catalyst to watch: Sales uptake and further label expansions.
Main risk: Competition or pricing pressure may limit revenue.
Why it matters
EU label expansion widens the addressable patient pool for RINVOQ, supporting incremental revenue for the drug franchise.
Details
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1 Approval was based on the open-label Phase 1...
Related assets & topics
HealthcareEuropeSources
- prnewswire · 2026-09-22 06:00 UTC